Strategies for the Management of Atrial Fibrillation in patiEnts Receiving Dialysis

Model scores of the 29,894 trials active now.

Model score 22% for any early termination, 9% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 15% of the time (446 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2022-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: dialysisreceivingdonoratrialenrollment
  Phrases that lowered it: the effecteffect ofecgevaluate the65
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 6.5% (lowers risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 35 (lowers risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: parallel (raises risk) · Design
• Number of arms: 3 (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Collaborators: 2 (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports with a death: 13.0% (lowers risk) · Drug's FDA history
• Sponsor's past trials: 123 (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Blinding: none (raises risk) · Design
• Drug's FAERS reports before start: 223785 (lowers risk) · Drug's FDA history
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Drug's FAERS reports in the prior 12 months: 40705 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD) NCT02933697 · started 2017 · scored riskier than 80% of active trials completed
• Study of Apixaban in Patients Receiving Hemodiafiltration NCT04952792 · started 2021 · scored riskier than 55% of active trials completed
• Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF) NCT02072434 · started 2014 · scored riskier than 42% of active trials completed
• First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Persistent Atrial Fibrillation Treatment (RAAFT-3) NCT04037397 · started 2019 · scored riskier than 85% of active trials completed
• Permanent Atrial fibriLLAtion Outcome Study Using Dronedarone on Top of Standard Therapy NCT01151137 · started 2010 · scored riskier than 71% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.